Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
| Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
| Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Qulipta | atogepant | Migraine, prevention | Active | |||
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | ||
| Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
| Ravicti | glycerol phenylbutyrate | Urea cycle disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | ||
| Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | ||
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
| Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete | ||
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
| Remsima | infliximab | Rheumatoid arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Remsima | infliximab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Active | ||
| Remsima | infliximab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Active | ||
| Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn | |||
| Renflexis | infliximab | rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024